Press release
Investigation announced for Investors in shares of Iovance Biotherapeutics, Inc. (NASDSQ: IOVA)
An investigation for investors in Iovance Biotherapeutics, Inc. (NASDSQ: IOVA) shares over potential securities laws violations.
Investors who purchased shares of Iovance Biotherapeutics, Inc. (NASDSQ: IOVA), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on whether a series of statements by Iovance Biotherapeutics, Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
San Carlos, CA based Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. Iovance Biotherapeutics, Inc. reported that its Net Loss increased from $197.55 million in 2019 to $259.58 million in 2020.
On May 18, 2021, Iovance Biotherapeutics, Inc. updated the public on its lead asset, the melanoma treatment lifileucel. Iovance Biotherapeutics, Inc. stated that, after receiving feed back from the U.S. Food and Drug Administration (“FDA”) regarding potency assays for lifileucel, the Company was planning to delay its submission of a biologics license application (“BLA”) for lifileucel until the second half of 2021.
Then, on May 19, 2021, the Company filed a Form 8-K with the SEC which announced that the Company’s Chief Executive Officer, Maria Fardis, was resigning as President, CEO and a director of the Company.
Shares of Iovance Biotherapeutics, Inc. (NASDSQ: IOVA) declined from $54.21 per share in January 2021 to as low as $15.88 per share on May 19, 2021.
Those who purchased shares of Iovance Biotherapeutics, Inc. (NASDSQ: IOVA) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Investigation announced for Investors in shares of Iovance Biotherapeutics, Inc. (NASDSQ: IOVA) here
News-ID: 2290263 • Views: …
More Releases from Shareholders Foundation
Lawsuit for Investors in Sonder Holdings Inc. (NASDAQ: SOND) filed in effort to …
An investor, who purchased shares of Sonder Holdings Inc. (NASDAQ: SOND), filed a lawsuit over alleged violations of Federal Securities Laws by Sonder Holdings Inc in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Sonder Holdings Inc. (NASDAQ: SOND) have certain options and for certain investors are short and strict deadlines running. Deadline: June 10, 2024. NASDAQ: SOND investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
Lawsuit filed for Investors in Ocugen, Inc. (NASDAQ: OCGN) in effort to recover …
An investor, who purchased shares of Ocugen, Inc. (NASDAQ: OCGN), filed a lawsuit i over alleged violations of Federal Securities Laws by Ocugen, Inc..
Investors who purchased shares of Ocugen, Inc. (NASDAQ: OCGN) have certain options and for certain investors are short and strict deadlines running. Deadline: June 10, 2024. NASDAQ: OCGN investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
Malvern, PA based Ocugen, Inc., a…
Investors who lost money with shares of Evolv Technologies Holdings, Inc. (NASDA …
An investor, who purchased shares of Evolv Technologies Holdings, Inc. (NASDAQ: EVLV), filed a lawsuit in the U.S. District Court for the District of Massachusetts over alleged violations of Federal Securities Laws by Evolv Technologies Holdings, Inc. f/k/a NewHold Investment Corp.
Investors who purchased shares of Evolv Technologies Holdings, Inc. (NASDAQ: EVLV) have certain options and for certain investors are short and strict deadlines running. Deadline: May 24, 2024. NASDAQ: EVLV…
Investigation announced for Investors who purchased shares of Comtech Telecommun …
Comtech Telecommunications Corp is under investigation over potential securities laws violations in connection with certain financial statements.
Investors who purchased shares of Comtech Telecommunications Corp. (NASDAQ: CMTL), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on whether a series of statements by Comtech Telecommunications Corp. regarding its business, its prospects and its operations were materially false…
More Releases for Iovance
Malignant Melanoma Pipeline Assessment | Insights into the Current Therapies, Em …
"Malignant Melanoma Pipeline Insight, 2022" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Malignant Melanoma Therapeutics Market.
The report provides a detailed description of the drug, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any).
The report also covers commercial and clinical activities of the pipeline products…
Small Lymphocytic Lymphoma Pipeline Assessment | Insights into the Current Thera …
As per DelveInsight's assessment, globally, nearly 80+ key pharma and biotech companies are working on 80+ pipeline drugs in the Small Lymphocytic Lymphoma therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA) and molecule types. Several of the therapies are in the advanced stages of clinical development expected to launch in the coming years.
"Small Lymphocytic Lymphoma Pipeline Insight, 2022" report by DelveInsight provides a comprehensive…
Tumor-Infiltrating Lymphocytes Market to Bolster the Growth during the Forecast …
Tumor-Infiltrating Lymphocytes Therapy exhibits significant potential for the treatment of advanced melanoma in clinical environments. ATMPs, in general, are reckoned as a personalized approach for cancer treatment. Tumor-infiltrating lymphocytes (TILs) are an important prognostic factor in melanoma and are associated with better outcomes in epithelial ovarian cancer.
An increase in focus on developing tumor-infiltrating lymphocytes due to several benefits contributes to the growth of the global tumor-infiltrating lymphocytes market. The National…
Tumor Infiltrating Lymphocyte (TIL) Market Key Players and Production Informatio …
The new study on the Global Tumor Infiltrating Lymphocyte (TIL) Market 2021-2027 analyzes the crucial capabilities, key infrastructures, major organizations, evaluates measures to attain potential success in the Tumor Infiltrating Lymphocyte (TIL) industry. Because of the in-depth overview of the world Tumor Infiltrating Lymphocyte (TIL) market, the recent document allows investors, traders, and manufacturers to plan some innovative techniques, and meanwhile, align them with operational and commercial enterprise models. Additionally, the Tumor…
Tumor Infiltrating lymphocytes Market to Bolster the Growth during the Forecast …
Tumor Infiltrating Lymphocytes Therapy, exhibit significant potential for the treatment of advanced melanoma in clinical environments. ATMPs, in general, are reckoned as personalized approach for cancer treatment.
Tumor infiltrating lymphocytes (TILs) are an important prognostic factor in melanoma and are associated with better outcomes in epithelial ovarian cancer.
Increase in focus on developing tumor infiltrating lymphocytes due to several benefits contributes to the growth of global tumor infiltrating lymphocytes market.
The…
Investigation announced for Long-Term Investors in shares of Iovance Biotherapeu …
Certain directors of Iovance Biotherapeutics, Inc are under investigation over potential breaches of fiduciary duties.
Investors who purchased shares of Iovance Biotherapeutics, Inc. (NASDSQ: IOVA) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain Iovance Biotherapeutics directors breached their fiduciary duties and caused damage to the company and its shareholders.
San Carlos, CA based Iovance Biotherapeutics,…
